New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 2, 2014
06:07 EDTACORAcorda Therapeutics reports FDA issues CRL for Plumiaz
Acorda Therapeutics announced that the FDA has issued a Complete Response Letter, or CRL, for the New Drug Application for Plumiaz Nasal Spray for the treatment of people with epilepsy who experience cluster seizures. A CRL is a communication from the FDA that informs a company that their review of the NDA is complete and the application cannot be approved in its present form. The company is currently developing a response to address the items outlined in the letter.
News For ACOR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 27, 2015
09:49 EDTACORAcorda Therapeutics gets another IPR challenge from Hayman group
The Coalition For Affordable Drugs, a group linked to Hayman Capital's Kyle Bass, has requested an Inter Partes Review of Claims 1–3, 5–8, and 10–41 of U.S. Patent No. 8,007,826 held by Acorda Therapeutics (ACOR), according to a USPTO filing. The patents relate to the company's multiple sclerosis treatment. BACKGROUND: On February 10, the same coalition requested an Inter Partes Review of claims 1–8 of “the ’685 patent” held by Acorda. On January 7, Reuters reported that Bass planned to take "around 15 pharmaceutical companies with a combined market capitalization of $450B" into an Inter Partes Review for extending patents in questionable ways, citing a presentation made by Bass in Oslo. PRICE ACTION: Shares of Acorda are down 2.6% to $34.62 in early trading.
February 24, 2015
07:33 EDTACORMaxim to hold a discussion
Subscribe for More Information
February 20, 2015
13:38 EDTACORLeerink specialty pharma analyst holds analyst/industry conference call
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use